JO3689B1 - صيغ من الباراسيتامول قابلة للحقن - Google Patents

صيغ من الباراسيتامول قابلة للحقن

Info

Publication number
JO3689B1
JO3689B1 JOP/2015/0303A JOP20150303A JO3689B1 JO 3689 B1 JO3689 B1 JO 3689B1 JO P20150303 A JOP20150303 A JO P20150303A JO 3689 B1 JO3689 B1 JO 3689B1
Authority
JO
Jordan
Prior art keywords
paracetamol
formulations
pharmaceutically acceptable
acceptable salt
slow
Prior art date
Application number
JOP/2015/0303A
Other languages
English (en)
Inventor
r patel Milan
J Shah Prakashchandra
R Patel Ketan
K Patel Asheel
Original Assignee
Troikaa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55022620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3689(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Troikaa Pharmaceuticals Ltd filed Critical Troikaa Pharmaceuticals Ltd
Application granted granted Critical
Publication of JO3689B1 publication Critical patent/JO3689B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<span dir="RTL">يتعلق الاختراع الحالي بحقن من الباراسيتامول منخفضة الكمية تعطى من خلال الوريد و ملحه المقبول دوائيا و طريقة تحضيره. توفر الصيغ تركيزا مرتفعا من الباراسيتامول أو ملحه المقبول دوائيا في نظام مذيب من الاختراع الحالي و الذي يمكن إعطاؤه ليس فقط من خلال مسار الإدخال في العضل أو الوريد بل أيضا يتناسب الإعطاء البطيء للأقراص عن طريق الوريد بعد حلها مع سوائل مائية إلى حجم نهائي لا يتجاوز 20 مل لتر. و تبقى هذه الصيغ القابلة للحقن مستقرة و تكون مناسبة أيضا للإعطاء من خلال المسار الوريدي البطيء مع آثار جانبية منخفضة (مثل التهاب الوريد، الألم، الخ).</span>
JOP/2015/0303A 2014-12-20 2015-12-09 صيغ من الباراسيتامول قابلة للحقن JO3689B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN4102MU2014 2014-12-20

Publications (1)

Publication Number Publication Date
JO3689B1 true JO3689B1 (ar) 2020-08-27

Family

ID=55022620

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0303A JO3689B1 (ar) 2014-12-20 2015-12-09 صيغ من الباراسيتامول قابلة للحقن

Country Status (28)

Country Link
US (1) US20180000940A1 (ar)
EP (1) EP3233055A1 (ar)
JP (1) JP2017538762A (ar)
KR (1) KR20170099911A (ar)
CN (1) CN107205924A (ar)
AR (1) AR103188A1 (ar)
AU (1) AU2015365533A1 (ar)
BR (1) BR112017012975B1 (ar)
CA (1) CA2969303A1 (ar)
CL (1) CL2017001629A1 (ar)
CO (1) CO2017006268A2 (ar)
CU (1) CU20170088A7 (ar)
DO (1) DOP2017000134A (ar)
EA (1) EA201791409A1 (ar)
EC (1) ECSP17038668A (ar)
IL (1) IL252729A0 (ar)
JO (1) JO3689B1 (ar)
MA (1) MA40599A1 (ar)
MD (1) MD20170071A2 (ar)
MX (1) MX2017008264A (ar)
PE (1) PE20171305A1 (ar)
PH (1) PH12017501005A1 (ar)
SG (1) SG11201704435PA (ar)
TN (1) TN2017000232A1 (ar)
TW (1) TWI649097B (ar)
UA (1) UA122136C2 (ar)
UY (1) UY36466A (ar)
WO (1) WO2016097899A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107229455B (zh) 2016-03-24 2019-09-17 阿里巴巴集团控股有限公司 一种业务处理方法、装置及系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
IT1301976B1 (it) * 1998-07-31 2000-07-20 Angelini Ricerche Spa Composizione farmaceutica iniettabile a base di paracetamolo
IT1313579B1 (it) 1999-07-30 2002-09-09 Acraf Composizione farmaceutica liquida a base di paracetamolo.
ITMI20012135A1 (it) 2001-10-16 2003-04-16 Bioren S A Soluzioni iniettabili pronte all'uso di paracetamolo
CN101217939A (zh) * 2005-05-27 2008-07-09 灵药生物技术有限公司 可注射组合物及制备这类组合物的方法
EP1973527B1 (en) * 2005-12-15 2009-10-07 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
AR067048A1 (es) 2007-06-18 2009-09-30 Combino Pharm Sl Formulaciones acuosas de acetaminofen para inyeccion.
EP2307056B1 (en) 2008-01-17 2021-12-15 Pharmis Biofarmacêutica, LDA Stabilized aqueous formulation containing paracetamol
MX2011003695A (es) * 2008-10-09 2011-08-17 A F S P A Aziende Chimiche Riunite Angelini Francesco A C R Formulacion farmaceutica liquida con contenido de paracetamol.
HUE054171T2 (hu) * 2010-06-30 2021-08-30 Troikaa Pharmaceuticals Ltd Paracetamolt tartalmazó gyógyászati kompozíciók és ejárás azok elõállítására
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN102258485A (zh) * 2011-01-11 2011-11-30 北京润德康医药技术有限公司 一种含对乙酰氨基酚的注射用制剂及其应用
CN102600068A (zh) * 2011-01-24 2012-07-25 联康药业克雷恩特塞提斯制药实验室有限责任公司 稳定即用的可注射扑热息痛制剂

Also Published As

Publication number Publication date
AU2015365533A1 (en) 2017-07-06
UY36466A (es) 2016-07-29
BR112017012975B1 (pt) 2023-09-26
JP2017538762A (ja) 2017-12-28
BR112017012975A2 (pt) 2018-02-27
PH12017501005A1 (en) 2017-12-11
AR103188A1 (es) 2017-04-19
EP3233055A1 (en) 2017-10-25
TN2017000232A1 (en) 2018-10-19
TWI649097B (zh) 2019-02-01
IL252729A0 (en) 2017-08-31
TW201622703A (zh) 2016-07-01
UA122136C2 (uk) 2020-09-25
KR20170099911A (ko) 2017-09-01
ECSP17038668A (es) 2017-12-01
EA201791409A1 (ru) 2017-10-31
CA2969303A1 (en) 2016-06-23
MD20170071A2 (ro) 2017-09-30
CN107205924A (zh) 2017-09-26
SG11201704435PA (en) 2017-06-29
MA40599A1 (fr) 2017-11-30
CL2017001629A1 (es) 2018-03-16
CO2017006268A2 (es) 2017-10-20
CU20170088A7 (es) 2018-03-13
PE20171305A1 (es) 2017-09-05
WO2016097899A1 (en) 2016-06-23
US20180000940A1 (en) 2018-01-04
MX2017008264A (es) 2017-10-02
DOP2017000134A (es) 2017-09-15

Similar Documents

Publication Publication Date Title
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
HRP20200704T1 (hr) Vodena formulacija koja sadrži paracetamol i ibuprofen
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
AR098386A1 (es) Formulación para gonadotropinas
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
PH12017501005A1 (en) Injectable formulations of paracetamol
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
EA201890788A1 (ru) Препараты оланзапина с замедленным высвобождением
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
PH12014502494A1 (en) Parenteral esmolol formulation
EA201391512A1 (ru) Твердая фармацевтическая композиция
RU2012123182A (ru) Способ коррекции психического состояния пациентов и антиоксидантого статуса при органическом расстройстве личности
MX2018001041A (es) Concentrado que contiene alprostadil.
EA201501157A1 (ru) Стабилизированная лекарственная форма коньюгата этидроната с цитарабином и её применение
RU2014142874A (ru) Способ лечения похмельного синдрома у лиц, не относящихся к больным алкоголизмом
TH155633A (th) สูตรผสมแบบฉีดของเอสโมลอล
GR1008260B (el) Ενδοφλεβιο σκευασμα λινεζολιδης και μεθοδος για την παρασκευη αυτου